Catalog No.
Product Name
Application
Product Information
Citations
-
CDK Inhibitor
CDK7-IN-22 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with demonstrated antitumor activity. Its inhibition of CDK7 plays a crucial role in modulating transcriptional regulation and cell cycle progression, making it a valuable tool for cancer research. CDK7-IN-22 is suitable for studies on tumorigenesis, therapeutic resistance, and cellular proliferation pathways. -
CDK7 Inhibitor
CDK7-IN-14 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), a key enzyme involved in transcriptional regulation and cell cycle progression. This pyrimidinyl derivative exhibits significant potential in cancer research, particularly in the study of tumors characterized by transcriptional dysregulation. CDK7-IN-14 may serve as a valuable tool for investigating therapeutic strategies targeting CDK7 in various malignancies. -
CDK Inhibitor
(+)-Atuveciclib is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) and the positive transcription elongation factor b (P-TEFb). With an IC50 value of 13 nM, it effectively suppresses CDK9 in cellular assays. This compound is primarily utilized in research related to transcription regulation and cancer therapeutics, offering insights into CDK9-mediated pathways and their role in various malignancies. -
CDKI Inhibitor
CDKI-IN-1 is a potent cyclin-dependent kinase inhibitor (CDKI) designed for investigating the role of CDK modulation in central nervous system (CNS) degenerative diseases. It effectively inhibits CDK activity, thereby providing insight into cell cycle regulation and neuronal cell survival. This compound is valuable for exploring therapeutic strategies targeting CDK pathways in neuroscience research. -
CDK4/6 Inhibitor
Crozbaciclib fumarate is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), with IC50 values of 3 nM and 1 nM, respectively. This compound effectively regulates cell cycle progression by hindering the phosphorylation of retinoblastoma protein, thereby halting proliferation in various cancer cell lines. Crozbaciclib fumarate is utilized in oncology research, particularly in studies investigating the therapeutic potential of targeting CDK4/6 in tumor growth and resistance mechanisms. -
PTEFb/CDK9 Inhibitor
BAY-1112054 hydrochloride is a potent inhibitor of PTEFb/CDK9, demonstrating high selectivity within the cyclin-dependent kinase family. This compound exhibits significant antiproliferative activity against various cancer cell lines, including HeLa and MOLM-13. BAY-1112054 hydrochloride is characterized by good metabolic stability and effectively suppresses tumor growth in mouse xenograft models while maintaining a favorable toxicity profile. Its mechanism and efficacy make it a valuable tool for cancer research applications. -
CDK4/6 PROTAC Degrader
CST651 is a selective proteolysis-targeting chimera (PROTAC) degrader specifically designed to target cyclin-dependent kinases CDK4 and CDK6. This compound effectively degrades CDK4 and CDK6 in MM.1S cells, exhibiting DC50 values of 20 nM and 5.1 nM, respectively. CST651 demonstrates the ability to inhibit cancer cell proliferation and migration, making it a valuable tool for research into various cancers, including acute lymphoblastic leukemia. -
CDK9 Inhibitor
SLM6 is a potent CDK9 inhibitor, specifically targeting the CDK9/cyclin K and CDK9/cyclin T1 complexes with IC50 values of 280 nM and 133 nM, respectively. In addition, SLM6 also effectively inhibits CDK1/cyclin B and CDK2/cyclin A, demonstrating IC50 values below 300 nM. This compound has been shown to induce apoptosis in multiple myeloma cells, making it a valuable tool for research in cancer biology and therapeutic development for hematological malignancies. -
CDK1/2 Inhibitor
Xylocydine is a potent inhibitor of cyclin-dependent kinases CDK1 and CDK2, demonstrating IC50 values of 1.4 nM and 61 nM, respectively. This compound effectively disrupts CDK activity, contributing to the regulation of apoptotic processes. Additionally, Xylocydine downregulates the levels of phosphorylated nucleolin and retinoblastoma protein, making it a valuable tool for investigations into cell cycle regulation and cancer research. -
CDK7 Inhibitor
CDK7-IN-18 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7). This pyrimidinyl derivative exhibits significant potential in the investigation of various cancers, particularly those associated with transcriptional dysregulation. CDK7-IN-18 serves as a valuable tool for research applications focused on understanding tumorigenesis and exploring therapeutic strategies targeting CDK7-mediated pathways. -
CDK2 Inhibitor
CDK2-IN-8 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 value of 1.74 µM. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studying cancer biology. CDK2-IN-8 is particularly relevant for research applications focused on melanoma and related malignancies, where CDK2 activity plays a crucial role in cell cycle regulation and tumor progression. -
CDK5 Inhibitor
CDK5-IN-2 is a highly selective cyclin-dependent kinase 5 (CDK5) inhibitor, exhibiting IC50 values of 0.2 nM against CDK5/p25 and 23 nM against CDK2/CycA. It serves as a valuable tool in research focused on neurodegenerative diseases, as CDK5 plays a critical role in neuronal function and development. This compound enables the exploration of CDK5's involvement in various cellular processes and its potential as a therapeutic target. -
CDK2 Degrader
CDK2 Degrader 8 is a novel chemical probe designed to target and degrade cyclin-dependent kinase 2 (CDK2). By specifically modulating CDK2 levels, it demonstrates significant anti-tumor activity, making it a valuable tool for investigating solid tumors such as breast cancer and ovarian serous cystadenocarcinoma, as well as liquid tumors like diffuse large B-cell lymphoma and acute myelogenous leukemia. CDK2 Degrader 8 facilitates research into the pathological roles of CDK2 dysregulation in cancer. -
CDK2 Inhibitor
TrkA Inhibitor is a selective CDK2 inhibitor, demonstrating an IC50 of 0.69 μM against CDK1. This compound is particularly valuable in research focused on chemotherapy-induced alopecia, allowing for the investigation of mechanisms involved in hair follicle cycling and potential therapeutic interventions. Its specificity for CDK2 makes it a useful tool in examining cell cycle regulation and associated pathways in various biological contexts. -
CDK9 Inhibitor
CDK9-IN-19 is a selective inhibitor of Cyclin-Dependent Kinase 9 (CDK9), exhibiting a potent IC50 value of 2.0 nM. This compound demonstrates significant antiproliferative activity in cellular assays and effectively suppresses tumor growth in MV4-11 xenograft models. With moderate pharmacokinetic properties and minimal hERG inhibition, CDK9-IN-19 is valuable for research on acute myeloid leukemia (AML) and related oncogenic pathways. -
CDK9 Inhibitor
CDK9-IN-22 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) with an IC50 of 10.4 nM for CDK9, demonstrating significant efficacy in disrupting cellular pathways. This compound is known to induce apoptosis and promote cell cycle arrest at the G2/M phase. Additionally, CDK9-IN-22 decreases the levels of phosphorylated RNA polymerase II (S2) and CDK9 protein, exhibiting notable antiproliferative and anti-tumor properties. It is a valuable tool for research in cancer biology and therapeutic applications targeting CDK9-related pathways. -
CDK Inhibitor
P18IN005 hydrochloride is a selective inhibitor of cyclin-dependent kinase (CDK), primarily targeting p18. This compound effectively regulates hematopoietic stem cell (HSC) self-renewal, demonstrating superior potency compared to p27 in mouse models. P18IN005 hydrochloride enhances the expansion of functional HSCs in short-term cultures, making it a valuable reagent for investigating the signaling pathways that govern stem cell self-renewal and differentiation processes. -
CDK4/6 Inhibitor
CDK4/6-IN-14 is a potent and highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), displaying IC50 values of 10 nM and 16 nM, respectively. This compound exhibits over 60-fold selectivity compared to CDK1, CDK2, CDK7, and CDK9, while demonstrating high specificity against a broader panel of 205 kinases. CDK4/6-IN-14 is valuable for research into cell cycle regulation and has potential applications in studying cancer therapeutics and targeted therapies. -
CDK9 Inhibitor
CDK9-IN-15 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcription elongation. By inhibiting CDK9, this compound effectively reduces the phosphorylation of RNA polymerase II, leading to decreased transcriptional activity of oncogenes. CDK9-IN-15 is primarily utilized in cancer research to explore therapeutic strategies that target transcriptional regulation in malignancies. -
CDK7 Inhibitor
CDK7-IN-13 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), with a pyrimidinyl derivative structure. This compound exhibits significant activity against cancer cells characterized by transcriptional dysregulation, making it a valuable tool for cancer research. Its application in studies targeting CDK7 may enhance the understanding of cancer biology and aid in the development of novel therapeutic strategies. -
CDK9 Inhibitor
CDK9-IN-48 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), demonstrating an IC50 value of 1.37 nM. This compound effectively suppresses the proliferation of a variety of cancer cell lines, making it a valuable tool in cancer research. CDK9-IN-48 is particularly relevant for studies focused on acute myeloid leukemia and prostate cancer, where targeting CDK9 may provide therapeutic benefits. -
CDK12/13 Inhibitor
CDK12/13-IN-1 is a selective inhibitor of cyclin-dependent kinases 12 and 13 (CDK12/13). This compound demonstrates significant antitumor activity by interfering with the phosphorylation of RNA polymerase II, thereby disrupting transcriptional regulation in cancer cells. CDK12/13-IN-1 is utilized in research focused on cancer biology, particularly in exploring therapeutic strategies for tumors exhibiting CDK12/13 dependency. -
CDK4/6 Inhibitor
Dalpiciclib isethionate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting the kinase activity of these enzymes, Dalpiciclib effectively disrupts the progression of the cell cycle from the G1 phase to the S phase, which reduces abnormal cellular proliferation. This compound is primarily utilized in cancer research, particularly in the study of breast cancer, where CDK4/6 dysregulation plays a critical role in tumor growth. -
CDK Inhibitor
CDK-IN-10 is a potent cyclin-dependent kinase (CDK) inhibitor that selectively blocks CDK activity. This compound has demonstrated significant antitumor effects, making it an invaluable tool for cancer research. Researchers can utilize CDK-IN-10 to investigate CDK regulation in cell cycle progression and explore its potential in therapeutic applications against various cancers. -
CDK8 Inhibitor
CDK8-IN-10 is a selective inhibitor of cyclin-dependent kinase 8 (CDK8), exhibiting an IC50 value of 8.25 nM. This compound is instrumental in the study of CDK8's role in cancer progression and may provide insights into therapeutic strategies targeting this kinase. Its potency and selectivity make it a valuable tool for cancer research applications. -
CDK Inhibitor
AG-12275 is a selective cyclin-dependent kinase (CDK) inhibitor that targets CDK2 and CDK5. It exhibits potent inhibition of cancer cell proliferation by disrupting the cell cycle progression. This compound is valuable for investigating the roles of CDKs in cancer biology and the development of novel therapeutic strategies targeting these pathways. -
CDK9 Inhibitor
CDK9-IN-46 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a crucial role in transcriptional regulation. This compound demonstrates significant biological activity in reducing the phosphorylation of RNA polymerase II, thereby inhibiting gene transcription associated with cancer cell proliferation. CDK9-IN-46 is utilized in cancer research to explore therapeutic strategies targeting CDK9-dependent pathways. -
CDK4/6 Inhibitor
CDK4/6-IN-16 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting a potent activity with an IC50 of 0.013 μM for CDK4. This compound has significant implications for the study of CDK4-mediated pathologies, particularly in cancer research. Its targeted inhibition of CDK4/6 may aid in the exploration of cell cycle regulation and therapeutic strategies for cancer treatment. -
CDK4/6 Inhibitor
YY173 is a selective dual inhibitor of CDK4 and CDK6, demonstrating IC50 values of 7.7 nM and 88 nM, respectively. This compound effectively inhibits the proliferation of Jurkat cells with an IC50 of 1.46 μM. YY173 serves as a valuable tool for research in cancer biology and is suitable for the synthesis of PROTAC CDK4/6 degrader 1, facilitating studies on targeted protein degradation. -
CDK7 Inhibitor
CDK7-IN-12 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), which is integral to transcriptional regulation and cell cycle control. This compound demonstrates significant capacity to impede the proliferation of malignant tumors in both in vitro and in vivo studies. CDK7-IN-12 is suitable for research applications focused on cancer biology and therapeutic development. -
CDK2 Inhibitor
CDK2-IN-36 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound exhibits significant anticancer activity by disrupting CDK2-mediated phosphorylation events, thereby promoting apoptosis and inhibiting tumor cell proliferation. CDK2-IN-36 is valuable for research focused on cancer biology, cell cycle regulation, and the development of targeted cancer therapies. -
CDK12/13 Inhibitor
CDK12/13-IN-2 is a covalent inhibitor targeting cyclin-dependent kinases 12 and 13, with IC50 values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. This compound effectively inhibits the proliferation of breast cancer cells and is particularly relevant for research into triple-negative breast cancer. Its selective action provides a valuable tool for studying the effects of CDK12/13 inhibition in cancer biology. -
CDK2 Inhibitor
CDK2-IN-46 is a highly selective cyclin-dependent kinase 2 (CDK2) inhibitor with an IC50 value of 0.3 nM. It demonstrates a significant selectivity of over 200-fold compared to other kinases, including CDK1, CDK4, CDK6, CDK7, and CDK9. This compound is valuable for studying cell cycle regulation and has shown improved pharmacokinetic profiles in both rat and cynomolgus monkey models, making it suitable for preclinical research in cancer biology and therapeutic development. -
CDK2/E Inhibitor
CDK2-IN-18 is a potent inhibitor of cyclin-dependent kinases CDK2/E and CDK4/D1, exhibiting IC50 values of 8 nM and 46 nM, respectively. This compound effectively inhibits tumor cell proliferation, making it valuable for cancer research applications, particularly in studying cell cycle regulation and exploring therapeutic strategies targeting CDK pathways. -
Cyclin A Inhibitor
CDK-IN-15 is a potent inhibitor of Cyclin A, exhibiting an IC50 value of 0.14 μM. This compound is useful for studying cell cycle regulation and the inhibition of cyclin-dependent kinases in cancer research. Its biological activity makes it a valuable tool in investigating the role of Cyclin A in various cellular processes and the development of novel therapeutic strategies. -
CDK Inhibitor
Tacaciclib is a selective cyclin-dependent kinase (CDK) inhibitor that exerts antineoplastic effects by disrupting cell cycle progression. It primarily targets CDK2 and CDK9, leading to the inhibition of cancer cell proliferation. This compound is useful in cancer research for exploring therapeutic pathways and mechanisms of resistance in tumor models. -
CDK8 Inhibitor
CDK8-IN-7 is a selective inhibitor of cyclin-dependent kinase 8 (CDK8), exhibiting a Kd of 3.5 nM. This compound demonstrates notable cytotoxicity across various cancer cell lines, including MOLM-13, OCI-AML3, MV4-11, NRK, and H9c2, with IC50 values ranging from 4.8 to 25 µM. CDK8-IN-7 is a valuable tool for investigating the role of CDK8 in acute myeloid leukemia (AML) and other related malignancies. -
CDK2/4 Inhibitor
CDK2/4-IN-2 is a potent dual inhibitor of cyclin-dependent kinases 2 and 4, exhibiting IC50 values below 100 nM. This compound is instrumental in cancer research, providing insights into cell cycle regulation and the therapeutic potential of targeting CDK pathways. Its efficacy in inhibiting CDK2 and CDK4 makes it a valuable reagent for investigating tumor cell proliferation and developing anti-cancer strategies. -
CDK Inhibitor
rel-(2S,3R)-Voruciclib is a selective cyclin-dependent kinase (CDK) inhibitor, specifically the (2S,3R)-enantiomer of Voruciclib. This compound exhibits potent inhibition of CDK activity, making it valuable for the study of cell cycle regulation and cancer therapeutics. Its oral bioavailability allows for convenient administration in research applications focused on tumor growth inhibition and cell proliferation modulation. -
CDK-7 Inhibitor
CDK7-IN-25 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of less than 1 nM. This compound plays a critical role in regulating transcription and cell cycle progression, making it a valuable tool in cancer research. CDK7-IN-25 can be utilized to investigate the effects of CDK7 inhibition on tumor cell proliferation and survival, as well as to explore its potential therapeutic applications in oncology. -
CDK Inhibitor
CDK2-IN-7 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), providing valuable insights into cancer biology. With an IC50 of less than 50 nM, it effectively disrupts CDK2 activity, facilitating studies on cell cycle regulation and tumor progression. This compound is useful for researchers investigating CDK-targeted therapies and cell proliferation in various cancer models. -
CDK4/6 Inhibitor
CDK4/6-IN-21 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting IC50 values of 3.88 nM and 3.31 nM for CDK4 and CDK6, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research, particularly in studies targeting cell cycle regulation and proliferation in various malignancies. Its potent inhibition of CDK4 and CDK6 positions it as a promising candidate for therapeutic development in oncology. -
CDK4/CDK6 Inhibitor
CDK4/6-IN-5 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), exhibiting binding affinities (Kis) of 0.2 nM for the CDK4/Cyclin D1 complex and 4.4 nM for the CDK6/Cyclin D3 complex. This compound demonstrates significant biological activity in interrupting cell cycle progression, making it a valuable tool for cancer research, especially in studies focused on tumor proliferation and therapeutic resistance mechanisms. Its potency and selectivity make CDK4/6-IN-5 an important reagent for investigating the roles of CDK4 and CDK6 in various cancer types. -
CDK8 Inhibitor
CDK8-IN-5 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with an IC50 of 72 nM. This compound exhibits significant anti-inflammatory activity, evidenced by a 43% enhancement in IL-10 levels. CDK8-IN-5 is applicable in research focusing on inflammatory bowel disease and related inflammatory conditions. -
CDK2 Inhibitor
Anticancer agent 30, a 3-arylidene-2-oxindole derivative, functions primarily as a selective inhibitor of cyclin-dependent kinase 2 (CDK2). This compound exhibits potent anticancer activity, making it a valuable tool for research in cancer biology and therapeutic development. Its ability to modulate CDK2 activity positions it as a promising candidate for investigations into cell cycle regulation and tumor progression. -
CDK Inhibitor
AG-024104 is a potent cyclin-dependent kinase (CDK) inhibitor, demonstrating Ki values of 2.3 nM for CDK1/cyclin B, 1.8 nM for CDK2/cyclin A, and 0.67 nM for CDK4/cyclin D. By effectively inhibiting the kinase activity of these CDKs, AG-024104 is valuable in studying cell cycle regulation and cancer pathways. This inhibitor is also utilized as a negative control in peripheral leukocyte toxicity studies during preclinical development. -
CDK2 Inhibitor
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG) is a specific inhibitor of cyclin-dependent kinase 2 (CDK2). It has demonstrated the ability to induce apoptosis in U2OS osteosarcoma cells in a dose-dependent manner, making it a valuable tool for studying CDK2-mediated cell cycle regulation. This peptide is suitable for research applications aimed at understanding the role of CDK2 in cancer biology and potential therapeutic interventions. -
CDK Inhibitor
CDK-IN-19 is a potent cyclin-dependent kinase (CDK) inhibitor that selectively targets CDK enzymes involved in cell cycle regulation. This compound demonstrates significant antiproliferative activity and is valuable for cancer research applications, particularly in studying CDK-mediated pathways and the effects of cell cycle disruption in oncogenesis. Its role as a CDK inhibitor makes it a crucial tool for investigating therapeutic strategies aimed at cancer treatment. -
CDK Inhibitor
SNX2-1-108 is a selective inhibitor of cyclin-dependent kinase 8 (CDK8). This compound plays a pivotal role in modulating transcriptional regulation and is essential for various cellular processes. Its inhibition of CDK8 activity has significant implications in cancer research, particularly in studying the regulatory pathways of gene expression and potential therapeutic interventions in CDK8-dependent malignancies. -
CDK2 Inhibitor
EF-4-177 is an allosteric inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 of 87 nM. This compound effectively interferes with spermatogenesis, making it a valuable tool for studying male reproductive biology and the regulatory mechanisms of cell cycle progression. Its oral activity enhances its utility in pharmacological research and potential therapeutic applications.
